Filing Details

Accession Number:
0001062993-22-015042
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-06-16 21:53:28
Reporting Period:
2022-06-14
Accepted Time:
2022-06-16 21:53:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1621443 Zynerba Pharmaceuticals Inc. ZYNE () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1073407 L Daniel Kisner C/O Zynerba Pharmaceuticals, Inc.
80 W. Lancaster Avenue, Suite 300
Devon PA 19333
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-06-14 23,109 $0.00 28,109 No 4 A Direct
Common Stock Disposition 2022-06-14 40 $1.01 28,069 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2022-06-14 34,663 $0.00 34,663 $1.01
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
34,663 2032-06-14 No 4 A Direct
Footnotes
  1. The restricted stock award vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders.
  2. This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
  3. The option vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders.